|
Rosiglitazone in the Treatment of HIV-Associated Hyperlipidemia Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment by using a genuine medical doctor. We aren't mDs. Always confer with your doctor on Rosiglitazone in the Treatment of HIV-Associated Hyperlipidemia conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. Rosiglitazone in the Treatment of HIV-Associated Hyperlipidemia Clinical research trials and Rosiglitazone in the Treatment of HIV-Associated Hyperlipidemia healthcare trials occur in a lot of of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new does drugs. The role of the studies / undertakings is to solve specific human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to find treatments for all kinds of conditions, including Rosiglitazone in the Treatment of HIV-Associated Hyperlipidemia. Rosiglitazone in the Treatment of HIV-Associated Hyperlipidemia Clinical Trials and other clinical trials allow for volunteers to access health treatment choices before they are available to the general public. Many times the test subjects get treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Rosiglitazone in the Treatment of HIV-Associated Hyperlipidemia clinical trial. Test subjects typically receive the most effective healthcare possible for their Rosiglitazone in the Treatment of HIV-Associated Hyperlipidemia condition. Risks are a reality, nonetheless, and could include extra or frequent dr. calls, health hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "R" Clinical Trials Conditions > Rosiglitazone in the Treatment of HIV-Associated Hyperlipidemia  Rosiglitazone in the Treatment of HIV-Associated Hyperlipidemia
Rosiglitazone in the Treatment of HIV-Associated Hyperlipidemia
For Condition: Hyperlipidemia,HIV Infections
Status: Completed
Sponsor(s): National Center for Research Resources (NCRR) ,
Synopsis: The purpose of this research is to study the effects of rosiglitazone, a drug usually taken for Type II diabetes, on HIV-associated hyperlipidemia. HIV-associated lipodystrophy is a medical condition characterized by gradual changes in the distribution of body fat. The body fat located in the extremities and face disappears while body fat around the abdomen and upper back increases. Certain biochemical changes occur in association with these changes in fat distribution. Lipid levels particularly serum triglycerides are increased. HDL, the "good cholesterol" is decreased. Higher than normal level of insulin or insulin resistance is also found in this condition. This latter condition is one of the hallmarks of Type II diabetes. The protease inhibitors, a class of HIV medications, are associated with the occurrence of HIV-associated lipodystrophy. It has been suggested that a biochemical pathway known as the peripheral peroxisomal activating receptor (PPAR) gamma system is blocked leading to the onset of this condition. Rosiglitazone is a new drug approved by the FDA in 1999 for the treatment of type II diabetes. It lowers blood sugar by improving insulin resistance, which as mentioned before, is the hallmark of Type II diabetes. It has also been noted to improve blood lipid levels. Rosiglitazone works by stimulating the PPAR gamma system. It is hoped that this drug can turn on the PPAR system and reverse the HIV-associated lipodystrophy syndrome.
Details:
Eligibility:
Study Type: Interventional, Treatment, Open Label
Minimum Age/Maximum Age: 18 Years/75 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - HIV-positive with CD4 count > 500 and undetectable viral load - Treated with protease inhibitors for more than three months - Serum triglycerides > 400mg/dl - Clinical diagnosis of HIV-associated lipodystrophy - No history of type II diabetes - Fasting blood sugar < 126 mg/dl - No history of liver disease - Negative Hepatitis B antigen and Hepatitis C antibody - Not on the following medications: warfarin, digoxin, nifedipine, erythromycin, cyclosporine or HMG coA-reductase inhibitors - Hemoglobin > 11g/dl - Women of childbearing age must consent to barrier contraception
Total Enrollment:
Location and Contact Information:
Division of Endocrinology
New York City, New York, 10016
United States
Additional Information:
Study ID Numbers: NCRR-M01RR00096-1006; M01RR00096
Study Start Date:
Record last reviewed: January 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00006493
Other Hiv Infections Studies:
1. Nystatin Pastilles for the Prevention of Oral Candidiasis in Patients With AIDS or ARC
2. A Comparison of Two Dose Levels of Indinavir Combined with Two Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs) in HIV-Infected Patients
3. Curb, Alter, Lower, or Manage Stress in HIV: CALMS-HIV
4. Hormone Replacement Therapy and Anti-HIV Drugs in HIV-Infected, Postmenopausal Women
5. A Phase III Randomized, Double-Blind, Controlled Study of the Use of Anti-HIV Immune Serum Globulin (HIVIG) for the Prevention of Maternal-Fetal HIV Transmission in Pregnant Women and Newborns Receiving Zidovudine (AZT)
Related Studies:
Other HIV Infections Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials
Rosiglitazone in the Treatment of HIV-Associated Hyperlipidemia
|
|
|
|
|
|
|
|
